11 Commerce Drive
First Floor
Cranford, NJ 07016
United States
908 967 6677
https://citiuspharma.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 22
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Leonard L. Mazur | Co-Founder, CEO, Chairman & Secretary | 676,88k | N/D | 1945 |
Mr. Myron Z. Holubiak | Co-Founder & Executive Vice Chairman | 641,25k | N/D | 1947 |
Dr. Myron S. Czuczman M.D. | Executive VP & Chief Medical Officer | 571,38k | N/D | 1960 |
Mr. Jaime Bartushak | Chief Business Officer, CFO & Chief Accounting Officer | 527,97k | N/D | 1968 |
Mr. Gary F. Talarico | Executive Vice President of Operations | N/D | N/D | 1955 |
Ms. Ilanit Allen | Vice President of Investor Relations & Corporate Communications | N/D | N/D | N/D |
Dr. Alan Lader Ph.D. | Senior VP and Head of Clinical Operations & Quality Assurance | N/D | N/D | N/D |
Mr. Dhananjay G. Wadekar | Senior Vice President of Business Strategy | N/D | N/D | 1954 |
Mr. Kelly Creighton Ph.D. | Executive Vice President of Chemistry, Manufacturing & Controls | N/D | N/D | N/D |
Mr. Nikolas Burlew | Executive Vice President of Quality Assurance | N/D | N/D | N/D |
Citius Pharmaceuticals, Inc., a late-stage biopharmaceutical company, engages in the development and commercialization of critical care products. The company's diversified pipeline includes two late-stage product candidates, Mino-Lok and LYMPHIR. The company has enrollment in a Phase 3 pivotal trial of Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections. Its biologics license application for LYMPHIR, a novel IL-2R immunotherapy for an initial indication in cutaneous T-cell lymphoma is under review by the FDA. Its LYMPHIR also received orphan drug designation by the FDA for the treatment of CTCL and PTCL. In addition, the company is developing CITI-002 (Halo-Lido), which is in Phase 2b trial for the relief of hemorrhoids. The company was founded in 2007 and is headquartered in Cranford, New Jersey.
L'ISS Governance QualityScore di Citius Pharmaceuticals, Inc. al 1 luglio 2024 è 6. I criteri di valutazione fondamentali sono revisione: 10; Consiglio di Amministrazione: 8; diritti degli azionisti: 1; retribuzione: 7.